Display Settings:

Format

Send to:

Choose Destination
Pharmacoeconomics. 2002;20(8):553-63.

Economic benefits of amlodipine treatment in patients with coronary artery disease.

Author information

  • 1The Analytica Group, New York 10016, USA. rcasciano@theanalyticagroup.com

Abstract

OBJECTIVE:

To estimate the potential savings in overall cardiovascular disease (CVD) treatment costs for the US population with coronary artery disease (CAD) resulting from the use of amlodipine.

STUDY DESIGN AND METHODS:

Using patient-level data from a retrospective analysis of the Prospective Evaluation of the Vascular Effects of Norvasc Trial (PREVENT), a randomised, placebo-controlled clinical trial (n = 825), we constructed a Markov cohort simulation model to estimate the health economic outcomes of patients with CAD treated with either amlodipine or placebo.

PERSPECTIVE:

Healthcare payer perspective.

RESULTS:

The expected number of CVD events for amlodipine recipients was significantly lower than the number of CVD events in the placebo cohort (p < 0.01). The net present value of the cost per patient for CVD treatment was estimated to be $US14 117 for amlodipine recipients and $US16 683 (1999 values, assuming a 3% discount rate) for placebo recipients over 3 years of follow-up with cost savings realised in the amlodipine cohorts after 6 months.

CONCLUSIONS:

According to the model, amlodipine results in an expected per patient cost savings of $US2566 over a 3-year period, mainly due to a reduction in hospitalisations for cardiovascular-related events and procedures.

PMID:
12109920
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Loading ...
    Write to the Help Desk